EnzymeRx Provides a Clinical Update on Pegsitacase




Gout and Tumor Lysis Syndrome Programs Moving Briskly


PARAMUS, NJ, February 22, 2010 / b3c newswire / - EnzymeRx, LLC, a clinical-stage biotechnology company, today announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase PEG 20), and the recent launch of a second clinical study.  Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.


The completed trial was a phase 1 safety, pharmacokinetic and pharmacodynamic study of single ascending intravenous doses of pegsitacase (study details available at ClinicalTrials.gov).  The study sequentially enrolled five cohorts of four subjects each, with each cohort receiving escalating single doses of pegsitacase administered by intravenous infusion over one hour, without any premedication.  Tony Fiorino, MD, PhD, President and Chief Executive Officer of EnzymeRx, remarked: “It is truly gratifying to have completed enrollment in our first clinical study of pegsitacase.  The drug was extremely well tolerated in these subjects, with no infusion reactions, and we are very pleased with the potency and duration of uric acid-lowering that we have seen thus far.  We plan to present the results from this study at a medical conference later in 2010.”


The recently launched phase 1b trial is studying the safety, pharmacokinetics and pharmacodynamics of single and multiple intramuscular doses of pegsitacase (study details available at ClinicalTrials.gov).  In this study, subjects are enrolling into escalating dose cohorts receiving either single doses or three biweekly doses of pegsitacase.  Data from this study are expected later this year.


John Bomalaski, MD, Chief Medical Officer of EnzymeRx, noted: “With the completion of the single dose intravenous study, EnzymeRx is now positioned to move pegsitacase forward in tumor lysis syndrome.  Similarly, the recently launched multi-dose intramuscular study will, once completed, allow pegsitacase to move into phase 2 development in gout.  We have a busy year planned in both indications, and are very excited by the clinical profile exhibited by pegsitacase in the single dose intravenous setting.”


Gout, a painful arthritic caused by the formation of uric acid crystals in the joints, and tumor lysis syndrome, a serious condition that can occur during the treatment of certain tumors, are both associated with elevated levels of uric acid.  Pegsitacase metabolizes poorly soluble uric acid into highly soluble allantoin, thus lowering uric acid levels, and its long half-life may provide for an extended duration of uric acid-lowering after with each single dose.



About pegsitacase
Pegsitacase (formerly called Uricase PEG 20) is a recombinant uricase derived from Candida utilis, modified by the attachment of multiple 20 kilodalton molecules of polyethylene glycol (PEG).  Uricase PEG 20 has a prolonged half-life and reduced immunogenicity compared with unmodified uricase, and has been well tolerated in preclinical studies and in a prior phase 1 study in gout patients.  EnzymeRx is developing Uricase PEG 20 for the treatment of refractory gout and the management of hyperuricemia associated with tumor lysis syndrome.


About EnzymeRx
EnzymeRx, LLC is a private, clinical stage biotechnology company developing enzyme-based therapeutics.  Our lead product is pegsitacase, currently in phase 1 clinical studies, and we are actively building our preclinical pipeline.  For more information about EnzymeRx, uricase, gout or tumor lysis syndrome, please visit www.enzymerx.com.



Tony Fiorino, MD, PhD
President and Chief Executive Officer
EnzymeRx, LLC
17 Arcadian Avenue, Suite 104
Paramus, NJ 07652
Phone: (201) 843-4424
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.